Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05815160 · ClinicalTrials.gov registry record · Phase 1
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
A Phase 1 study of Small Cell Lung Cancer Recurrent, sponsored by Debiopharm International.
- Active
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 13
- Study locations
NCT05815160 is a Phase 1 study of Small Cell Lung Cancer Recurrent that is active but no longer recruiting, run by Debiopharm International. The registered enrollment target is 34 participants. The trial reports 13 study locations across 3 states.
The verdict
NCT05815160, a Phase 1 study of Small Cell Lung Cancer Recurrent, is active but no longer recruiting, sponsored by Debiopharm International.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 13
- Study locations
Study Summary
The primary purpose of part 1 (dose escalation) of this study is to identify the recommended dose and to characterize the safety and tolerability of Debio 0123 in combination with carboplatin and etoposide. The primary purpose of part 2 (dose expansion) of this study is to characterize the safety and tolerability of Debio 0123 at the recommended dose when administered in combination with carboplatin and etoposide.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Etoposide
- DRUG Debio 0123
Study Locations (13)
Other
- Hospital Universitario de A Coruna - A Coruña
- Hospital Universitario Vall d'Hebron - Barcelona
- Hospital Clinic Barcelona - Barcelona
- Institut Catala D'Oncologia - Badalona - Barcelona
- Clinica Universidad de Navarra - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario HM Sanchinarro. START Madrid - Centro Integral Oncológico Clara Campal (CIOCC) - Madrid
- NEXT Oncology Madrid - Madrid
- Hospital Quironsalud Malaga - Málaga
- Clinica Universidad de Navarra - Pamplona
- Hospital Clinico Universitario de Valencia - Valencia
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05815160
The ClinicalTrials.gov registry entry for NCT05815160 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small Cell Lung Cancer Recurrent appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT05815160 reports 13 study locations spanning 3 distinct geographic areas - top geographies include Other, Arkansas, New York.
Frequently Asked Questions
What is clinical trial NCT05815160 about?
NCT05815160 is a clinical study titled "Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy". The primary purpose of part 1 (dose escalation) of this study is to identify the recommended dose and to characterize the safety and tolerability of Debio 0123 in combination with carboplatin and etoposide. The primary purpose of part 2 (dose expansion) of this study is to characterize the safety a...
What is the current status of trial NCT05815160?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2023-05-02. Estimated completion is 2026-03.
What conditions does trial NCT05815160 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer Recurrent.
What interventions are being tested in trial NCT05815160?
The interventions under investigation include: Carboplatin (DRUG), Etoposide (DRUG), Debio 0123 (DRUG).
Who is sponsoring clinical trial NCT05815160?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05815160 being conducted?
This trial has 13 study locations across Arkansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.